The cardioprotective effects disclosed by this study provide detailed mechanistic explanation for the important cardiac functional gain induced by the short-term S100A9 blockade, supporting this therapy as a potential future treatment for acute MI. The gene discussed is S100A9; the disease is myocardial infarction.